Display options
Share it on

J Fluoresc. 2011 Jan;21(1):355-64. doi: 10.1007/s10895-010-0724-z. Epub 2010 Oct 02.

The synthesis, X-ray crystal structure and optical properties of novel 5-aryl-3-ferrocenyl-1-pyridazinyl-pyrazoline derivatives.

Journal of fluorescence

Zhong-Liang Gong, Yong-Sheng Xie, Bao-Xiang Zhao, Hong-Shui Lv, Wei-Yong Liu, Liang-Wen Zheng, Song Lian

Affiliations

  1. Institute of Organic Chemistry, School of Chemistry and Chemical Engineering, Shandong University, Jinan, People's Republic of China.

PMID: 20890645 DOI: 10.1007/s10895-010-0724-z

Abstract

A series of novel 5-aryl-3-ferrocenyl-1-pyridazinyl pyrazoline derivatives was synthesized by the reaction of ferrocenyl chalcone and 3-chloro-6-hydrazinylpyridazine in 10-65% yields. The compounds were characterized using IR, (1)H NMR, HRMS spectroscopic techniques and representative compounds 3c and 4c were assigned based on the X-ray crystallographic structure. The absorption and fluorescence characteristics of the compounds were investigated in chloroform, tetrahydrofuran and acetonitrile, respectively. The results showed that the absorption maxima of the compounds varied from 323 to 327 nm depending on the groups bonded to benzene and pyridazine ring. The maximum emission spectra of compounds in CHCl(3) were dependent on groups in pyridazine ring in which a strong donating-electron group such as propoxyl group on pyridazine ring in N-1 position of pyrazoline made the emission wavelength of 4a-4e small red shifte than that of compounds 3a-3e with chlorine group. The intensity of absorption and fluorescence was also correlated with substituent on aryl ring in C-5 position of pyrazoline. In addition, the absorption spectra of these compounds changed very little, but the fluorescence spectra had much change with increasing solvent polarity.

References

  1. ChemMedChem. 2006 Oct;1(10):1119-25 - PubMed
  2. Spectrochim Acta A Mol Biomol Spectrosc. 2007 Oct;68(2):404-8 - PubMed
  3. Bioorg Med Chem. 2008 May 1;16(9):5171-80 - PubMed
  4. Eur J Med Chem. 2009 Jun;44(6):2606-10 - PubMed
  5. Talanta. 2009 Mar 15;77(5):1707-14 - PubMed
  6. Bioorg Med Chem Lett. 2008 Feb 1;18(3):918-22 - PubMed
  7. Bioorg Med Chem. 2009 Feb 1;17(3):981-9 - PubMed
  8. Eur J Med Chem. 2009 Jan;44(1):417-25 - PubMed
  9. Spectrochim Acta A Mol Biomol Spectrosc. 2009 Jul 15;73(2):221-5 - PubMed
  10. Bioorg Med Chem. 2009 Mar 1;17(5):1957-62 - PubMed
  11. Eur J Med Chem. 2009 Apr;44(4):1682-8 - PubMed
  12. Carbohydr Res. 2009 Jul 27;344(11):1270-5 - PubMed
  13. Eur J Med Chem. 2009 May;44(5):2172-7 - PubMed
  14. Bioorg Med Chem. 2008 Dec 15;16(24):10165-71 - PubMed
  15. Bioorg Med Chem. 2009 Jul 1;17(13):4718-23 - PubMed
  16. Guang Pu Xue Yu Guang Pu Fen Xi. 2009 Oct;29(10):2810-4 - PubMed
  17. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2299-302 - PubMed
  18. Eur J Med Chem. 2009 Apr;44(4):1396-404 - PubMed
  19. Spectrochim Acta A Mol Biomol Spectrosc. 2008 Dec 15;71(4):1327-32 - PubMed
  20. Bioorg Med Chem Lett. 2009 Jan 1;19(1):255-8 - PubMed
  21. Bioorg Med Chem. 2006 Jun 1;14(11):3929-37 - PubMed
  22. Bioorg Med Chem Lett. 2009 May 15;19(10):2688-92 - PubMed
  23. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2147-51 - PubMed
  24. Eur J Med Chem. 2008 Nov;43(11):2347-53 - PubMed
  25. Bioorg Med Chem. 2009 Jan 15;17(2):675-89 - PubMed
  26. Eur J Med Chem. 2009 Jun;44(6):2632-5 - PubMed
  27. Eur J Med Chem. 2009 Mar;44(3):1317-25 - PubMed
  28. Spectrochim Acta A Mol Biomol Spectrosc. 2009 Jul 15;73(2):281-5 - PubMed

Publication Types